Therefore, these data may indicate that the inhibition of the PI3K/AKT/mTOR pathway in CTCs may be a valuable target to block metastatic progression in CRC patients that should be confirmed in further xenograft mouse models in vivo. The gene discussed is AKT1; the disease is colorectal carcinoma.